IKZF4 Antibody

What is IKZF4 and why is it important in immunological research?

IKZF4 is a DNA-binding protein that belongs to the Ikaros family of transcription factors. It functions as a transcriptional repressor by binding to the 5'GGGAATRCC-3' Ikaros-binding sequence . With a molecular weight of approximately 64.1 kilodaltons, IKZF4 interacts with SPI1 and MITF to repress transcription of specific promoters through recruitment of corepressors SIN3A and CTBP2 .

IKZF4 plays essential roles in:

• Regulatory T-cell (Treg) inhibitory function

• FOXP3-mediated gene silencing in Tregs

• Central and peripheral nervous system development

• T helper cell differentiation

Its association with multiple autoimmune conditions, including type 1 diabetes, vitiligo, and alopecia areata, makes it a significant research target .

What are the common applications for IKZF4 antibodies in research?

IKZF4 antibodies are employed in multiple experimental techniques:

For optimal results, validation in your specific experimental system is essential, as performance can vary with sample type and preparation method.

How should I select the appropriate IKZF4 antibody for my experimental system?

Selection of an appropriate IKZF4 antibody requires consideration of several factors:

• Target region: Determine whether you need an antibody targeting the N-terminal, C-terminal, or internal regions. Different isoforms of IKZF4 exist (NP_071910.3, NP_001338019.1, NP_001338020.1, NP_001338021.1) , so choose antibodies recognizing your region of interest.

• Species reactivity: Verify cross-reactivity with your experimental species. Many antibodies react with human, mouse, and rat IKZF4, but species-specific differences exist .

• Antibody type:

  • Polyclonal antibodies: Broader epitope recognition but potential batch variation

  • Monoclonal antibodies: Consistent specificity but narrower epitope recognition

  • Recombinant antibodies: High consistency and reproducibility

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, etc.).

• Validation data: Review manufacturer's validation data, including positive controls in relevant cell lines (e.g., Raji, K-562, HepG2 cells for WB) .

What validation steps should I perform before using a new IKZF4 antibody?

Proper validation ensures reliable results with IKZF4 antibodies:

• Positive control testing: Use cell lines with known IKZF4 expression (Raji, K-562, HepG2, U2OS cells) .

• Specificity verification:

  • Western blot: Confirm band at expected molecular weight (~64 kDa)

  • Knockout/knockdown controls: Compare with IKZF4-depleted samples

  • Blocking peptide: Competition assay with immunizing peptide

• Optimization for your application:

  • Titration experiments to determine optimal concentration

  • Testing different blocking agents and incubation conditions

  • Comparing fixation methods for IHC/IF applications

• Cross-reactivity assessment: Test in samples from different species if working with non-human models.

• Lot-to-lot consistency: When reordering, verify performance against previous lots using standardized samples.

How can I optimize detection of IKZF4 in different T cell subpopulations?

IKZF4 expression varies across T cell subpopulations, requiring optimized detection strategies:

• Regulatory T cells (Tregs):

  • Co-staining with FOXP3 is essential as IKZF4 mediates FOXP3-mediated gene silencing

  • Use permeabilization protocols optimized for nuclear transcription factors

  • Consider fixation with paraformaldehyde followed by methanol for improved nuclear antigen access

• TH17 cells:

  • IKZF4 has been identified as part of the negative regulatory module for TH17

  • Combine with IL-17A staining for proper identification

  • Optimize stimulation conditions (e.g., PMA/ionomycin) to maintain detectable levels

• Vδ2 T cells:

  • TGF-β plus IL-15 treatment enhances IKZF4 expression in these cells

  • Flow cytometry analysis may require higher antibody concentrations (1:100-1:200)

  • Coordinate with IL-9 staining as IKZF4 is associated with IL-9 production in these cells

• T follicular helper cells (TFH):

  • Co-stain with Bcl-6 as IKZF4 (particularly Aiolos) cooperates with STAT3 to induce Bcl-6 expression

  • Consider cell sorting before Western blot analysis for purer populations

For all populations, start with 0.25 μg antibody per 10^6 cells for flow cytometry and adjust based on signal-to-noise ratio .

What are the methodological considerations when investigating IKZF4's role in Type 1 Diabetes (T1D) research?

IKZF4 has significant associations with T1D pathogenesis, requiring careful experimental design:

• Polymorphism analysis:

  • IKZF4 polymorphism (rs1701704) shows strong association with insulin autoantibody (IAA) positivity

  • Genotype samples using validated SNP assays

  • Include the INS gene polymorphism rs689 as comparison, as both modify IAA positivity

• Autoantibody correlation studies:

  • The presence of the susceptible C allele of IKZF4 marker is inversely associated with IAA

  • Design assays to simultaneously detect IAA, ICA, GADA, IA2A, and ZnT8A

  • Use standardized ELISA or radioimmunoassay methods for autoantibody detection

• T cell functional assays:

  • Investigate IKZF4's role in regulatory T cell suppressive function

  • Compare IKZF4 expression between patients with different T1D risk genotypes

  • Use flow cytometry with intracellular staining protocols optimized for transcription factors

• Tissue analysis from T1D models:

  • For pancreatic sections, use heat-induced epitope retrieval methods

  • Optimize blocking of non-specific binding in pancreatic tissue

  • Counter-stain with insulin and CD3 to correlate IKZF4 expression with insulitis

• Methodology validation:

  • Include appropriate controls reflecting different IKZF4 genotypes

  • Validate antibody specificity in the context of genetic polymorphisms

How can I effectively use IKZF4 antibodies for transcription factor activity assays?

Assessing IKZF4 transcription factor activity requires specialized approaches:

• Chromatin Immunoprecipitation (ChIP):

  • Use antibodies specifically validated for ChIP applications

  • Target the DNA-binding domain to ensure functional relevance

  • Sonication conditions for nuclear proteins should be optimized (typically 10-15 cycles)

  • Include positive control regions known to bind IKZF4 (Ikaros-binding sequence 5'GGGAATRCC-3')

• Transcription Factor Activity Assays:

  • Commercial IKZF4 Transcription Factor Activity Assays are available

  • These allow detection and qualitative analysis of endogenous levels of activated transcription factors

  • Prepare nuclear extracts with specialized buffers maintaining transcription factor binding capability

  • Include competitive and non-competitive controls to verify binding specificity

• Protein-Protein Interaction Studies:

  • Co-immunoprecipitation to study IKZF4 interactions with:

    • FOXP3 in regulatory T cells

    • SPI1 and MITF for transcriptional repression

    • SIN3A and CTBP2 corepressors

  • Use crosslinking protocols for transient interactions

  • Consider proximity ligation assays for in situ interaction verification

• Reporter Assays:

  • Design reporter constructs containing IKZF4 binding sequences

  • Include mutated binding site controls

  • When co-expressing IKZF4, verify expression by Western blot

  • Account for potential homodimerization and heterodimerization with other Ikaros family members

How do I interpret contradictory results when using different IKZF4 antibodies?

Contradictory results with different IKZF4 antibodies are relatively common due to several factors:

• Epitope differences:

  • Compare the immunogens used to generate each antibody:

    • N-terminal antibodies (e.g., AA 2-108)

    • Internal region antibodies (e.g., sequence RPTFIDRLANSLTKR)

    • C-terminal antibodies

  • Different epitopes may be differentially accessible in certain protein complexes

• Isoform specificity:

  • IKZF4 has multiple isoforms (NP_071910.3, NP_001338019.1, NP_001338020.1, NP_001338021.1)

  • Determine which isoforms each antibody recognizes

  • Verify predominant isoforms in your experimental system

• Post-translational modifications:

  • Phosphorylation or other modifications may block certain epitopes

  • Some antibodies may preferentially recognize modified or unmodified forms

  • Consider using phosphatase treatment controls

• Technical validation approach:

  • Use multiple antibodies targeting different regions in parallel

  • Implement genetic validation (siRNA, CRISPR knockout)

  • Compare results across different applications (WB vs. IF vs. Flow)

  • Quantify correlation between results from different antibodies

• Data interpretation strategy:

  • Create a consensus model based on consistent findings

  • Weight results from antibodies with more extensive validation

  • Consider context-dependent expression or modifications

What are the best methodological approaches for studying IKZF4's role in IL-9 production in T cells?

IKZF4 has been implicated in IL-9 production, particularly in Vδ2 T cells, requiring specialized methods:

• Cell culture optimization:

  • For Vδ2 T cells: TGF-β plus IL-15 strongly enhances IKZF4 and IL-9 expression

  • For CD4/CD8 T cells: TGF-β/IL-15 plus IL-4 is required for optimal IL-9 induction

  • Culture periods affect expression patterns (IL-9 reduced on day 15 compared to day 8)

• Detection methods comparison:

  • Intracellular flow cytometry: Best for single-cell analysis and co-expression studies

  • ELISA/Multiplex analysis: Preferred for quantitative secretion measurements

  • RT-qPCR: Most sensitive for transcriptional regulation studies

• Functional validation techniques:

  • IKZF4 knockdown/overexpression followed by IL-9 measurement

  • ChIP assays to determine if IKZF4 directly binds IL-9 promoter/enhancer regions

  • Luciferase reporter assays with IL-9 regulatory elements

• Co-expression analysis protocol:

  • Stimulate with TPA/ionomycin to induce cytokine expression

  • Co-stain for IL-9 and IFN-γ to identify double-positive populations

  • Include time-course analysis to capture optimal expression windows

• Comparative analysis framework:

  • Compare IKZF4/IL-9 relationship across T cell subsets (Vδ2 vs. CD4 vs. CD8)

  • Establish dose-response curves for TGF-β, IL-15, and IL-4

  • Correlate IKZF4 expression levels with IL-9 production quantitatively

How can IKZF4 antibodies be used to investigate its role in the FOXP3-mediated gene silencing mechanism?

IKZF4 mediates FOXP3-mediated gene silencing in regulatory T cells through specific molecular mechanisms:

• Co-immunoprecipitation protocol optimization:

  • Use formaldehyde crosslinking (1-2%) to capture transient interactions

  • Include DNase treatment to eliminate DNA-mediated associations

  • Sequential immunoprecipitation (Re-ChIP) to identify FOXP3-IKZF4 co-bound regions

  • Western blot verification with antibodies targeting different epitopes

• ChIP-seq experimental design:

  • Compare IKZF4 and FOXP3 binding profiles in regulatory T cells

  • Identify regions of co-occupancy as potential co-regulated genes

  • Include input controls and IgG precipitation negative controls

  • Validate key targets with ChIP-qPCR

• Functional analysis approach:

  • IKZF4 knockdown followed by assessment of FOXP3 target gene expression

  • Overexpression of IKZF4 mutants lacking specific domains

  • Reporter assays with FOXP3-responsive elements with/without IKZF4

  • Co-transfection experiments to assess cooperative repression

• CTBP1 corepressor recruitment analysis:

  • IKZF4 mediates recruitment of corepressor CTBP1

  • Proximity ligation assays to visualize protein-protein interactions in situ

  • Sequential ChIP for IKZF4 followed by CTBP1 at specific genomic loci

  • Identification of the IKZF4 domain necessary for CTBP1 interaction

• Single-cell analysis methodology:

  • Combined RNA-seq and ATAC-seq to correlate IKZF4 expression with chromatin accessibility

  • Single-cell western blotting for protein co-expression patterns

  • Mass cytometry (CyTOF) with metal-conjugated antibodies for multi-parameter analysis

What are the common pitfalls when using IKZF4 antibodies and how can they be addressed?

Several challenges can arise when working with IKZF4 antibodies:

• High background in immunostaining:

  • Cause: Insufficient blocking or antibody concentration too high

  • Solution: Optimize blocking (5% BSA or 10% normal serum from host species of secondary antibody)

  • Implement additional washing steps with 0.1-0.3% Triton X-100

  • Use antibody dilutions at the higher end of recommended range (e.g., 1:500 instead of 1:200)

• Multiple bands in Western blot:

  • Cause: Detection of multiple isoforms or degradation products

  • Solution: Compare to expected pattern from manufacturer's validation data

  • Use freshly prepared samples with protease inhibitors

  • Verify bands against known molecular weights of IKZF4 isoforms

  • Consider using knockout/knockdown controls to identify specific bands

• Poor signal in nuclear proteins:

  • Cause: Insufficient nuclear extraction or epitope masking

  • Solution: Use specialized nuclear extraction protocols with detergents

  • Try heat-mediated antigen retrieval for fixed samples

  • Consider alternative fixation methods (methanol vs. paraformaldehyde)

  • For ChIP applications, optimize crosslinking and sonication conditions

• Variability between experiments:

  • Cause: Antibody degradation or inconsistent sample preparation

  • Solution: Aliquot antibodies to avoid freeze-thaw cycles

  • Standardize cell culture conditions and activation protocols

  • Include positive control samples in each experiment

  • Document lot numbers and validate each new lot

How should I optimize IKZF4 antibody use for studying low expression levels in specific cell types?

Detecting low IKZF4 expression requires specialized approaches:

• Signal amplification techniques:

  • Tyramide signal amplification for immunohistochemistry/immunofluorescence

  • Enhanced chemiluminescence substrates with extended exposure for Western blot

  • Biotin-streptavidin amplification systems for flow cytometry

• Sample enrichment methods:

  • Nuclear extraction to concentrate transcription factors

  • Immunoprecipitation before Western blot for target enrichment

  • Cell sorting for population enrichment before analysis

• Protocol modifications:

  • Extended primary antibody incubation (overnight at 4°C)

  • Reduced washing stringency while maintaining specificity

  • Optimized permeabilization for nuclear protein access

  • Use of low-background detection systems

• Specialized equipment settings:

  • Flow cytometry: Increased voltage settings with careful compensation

  • Microscopy: Extended exposure time with background subtraction

  • Western blot: Longer exposure times with low-fluorescence membranes

• Validation strategies for low signals:

  • Parallel analysis with mRNA detection (qPCR or in situ hybridization)

  • Overexpression controls to confirm antibody functionality

  • Titration experiments to determine minimal detection threshold

How can emerging technologies enhance IKZF4 protein detection and functional analysis?

New technologies provide enhanced capabilities for IKZF4 research:

• Mass spectrometry-based approaches:

  • Targeted proteomics with IKZF4-specific peptides

  • Phosphoproteomics to identify regulatory post-translational modifications

  • Proximity-dependent biotin labeling (BioID, APEX) to map interaction networks

  • Cross-linking mass spectrometry to identify structural interactions

• Advanced microscopy techniques:

  • Super-resolution microscopy for precise nuclear localization

  • Live-cell imaging with fluorescent protein fusions

  • FRET/FLIM for direct protein-protein interaction visualization

  • Lattice light-sheet microscopy for dynamic studies in living cells

• Single-cell technologies:

  • Single-cell Western blotting for protein heterogeneity assessment

  • CITE-seq for combined protein and RNA analysis

  • Single-cell ATAC-seq to correlate IKZF4 levels with chromatin accessibility

  • Cellular indexing of transcriptomes and epitopes (CITE-seq)

• CRISPR-based approaches:

  • CUT&RUN or CUT&Tag as alternatives to ChIP for genomic binding sites

  • CRISPR activation/inhibition to modulate IKZF4 expression

  • CRISPR screens to identify IKZF4 functional partners

  • Base editing for studying specific IKZF4 variants

• Computational integration:

  • Multi-omics data integration frameworks

  • Machine learning for pattern recognition in IKZF4 binding profiles

  • Network analysis of IKZF4 interaction partners

  • Structural prediction of IKZF4 complexes with partners

What are the considerations for studying IKZF4 polymorphisms and their impact on immune regulation?

IKZF4 polymorphisms have significant implications for immune regulation and disease susceptibility:

• Genotyping approaches:

  • Target key SNPs with established associations (e.g., rs1701704 for T1D)

  • Use high-resolution HLA typing alongside IKZF4 genotyping

  • Consider haplotype analysis rather than single SNPs

  • Implement next-generation sequencing for comprehensive variant detection

• Functional characterization methodology:

  • Compare IKZF4 expression levels between risk and non-risk genotypes

  • Assess DNA binding affinity with electrophoretic mobility shift assays

  • Evaluate transcriptional activity using reporter gene assays

  • Measure protein-protein interactions with co-immunoprecipitation

• Phenotypic correlation analysis:

  • Autoantibody profiles (particularly IAA for T1D)

  • T cell subset distribution and function

  • Cytokine production patterns

  • Disease progression metrics

• Experimental design considerations:

  • Include sufficient sample sizes for statistical power

  • Account for ethnic background variation in polymorphism frequency

  • Consider epistatic interactions with other genetic loci

  • Implement matched case-control designs

• Translational research approaches:

  • Develop screening panels for risk assessment

  • Explore personalized intervention strategies based on genotype

  • Evaluate IKZF4-targeting therapeutic potential in genetic subgroups

  • Biomarker development incorporating genotype information